Dr. Lal PathLabs (NSE:LALPATHLAB) Other Financing: ₹0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:LALPATHLAB Dr. Lal PathLabs Ltd NSE:LALPATHLAB
93 GF Score
Price ₹1,949.90
GF Value ₹1,735.83
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Dr. Lal PathLabs Other Financing?

Dr. Lal PathLabs NSE:LALPATHLAB -0.21% 93 Other Financing is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:LALPATHLAB with a GF Score™ of 93/100 and a GF Value™ of ₹1,735.83 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Dr. Lal PathLabs's Other Financing for the three months ended in Jun. 2026 was ₹0 Mil.

Dr. Lal PathLabs's Other Financing for the trailing twelve months (TTM) ended in Jun. 2026 was ₹0 Mil.

Dr. Lal PathLabs Other Financing Historical Data

* Premium members only.

The historical data trend for Dr. Lal PathLabs's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dr. Lal PathLabs Other Financing Chart

Dr. Lal PathLabs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -304.00 -378.66 -293.59 -223.05 -228.00

Dr. Lal PathLabs Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:LALPATHLAB
93GF Score
Dr. Lal PathLabs Ltd NSE:LALPATHLAB
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dr. Lal PathLabs Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of ₹0 Mil mean?
Dr. Lal PathLabs (NSE:LALPATHLAB) has a Other Financing of ₹0 Mil as of Jun. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Dr. Lal PathLabs and its competitors.
Is Dr. Lal PathLabs' Other Financing too high?
Dr. Lal PathLabs' current Other Financing is ₹0 Mil. Overall, Dr. Lal PathLabs has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dr. Lal PathLabs' Other Financing compare to TMO and DHR?
Dr. Lal PathLabs' Other Financing of ₹0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Medical Diagnostics & Research company?
A good Other Financing depends on the Medical Diagnostics & Research industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Dr. Lal PathLabs and its competitors. Dr. Lal PathLabs's current Other Financing is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr. Lal PathLabs stock overvalued right now?
Based on GuruFocus' analysis, Dr. Lal PathLabs (NSE:LALPATHLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,735.83, compared to a current price of ₹1,949.90 — trading 12.3% above its estimated fair value. The current Other Financing is ₹0 Mil. Dr. Lal PathLabs' overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Dr. Lal PathLabs (NSE:LALPATHLAB), the current Other Financing is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Dr. Lal PathLabs stock appears to be overvalued. The current stock price of ₹1,949.90 is trading 12.3% above its estimated GF Value™ of ₹1,735.83. GuruFocus considers Dr. Lal PathLabs to be Modestly Overvalued.

Key valuation signals for NSE:LALPATHLAB:

  • Other Financing: ₹0 Mil
  • GF Value™: ₹1,735.83 vs. price of ₹1,949.90 (12.3% above fair value)
  • GF Score™: 93/100 with 5 warning signs

No single metric tells the full story. See the NSE:LALPATHLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dr. Lal PathLabs Business Description

Other Exchanges 539524:India
Address 12th Floor, Tower B, SAS Tower, Sector 38, Medicity, Gurugram, HR, IND, 122 001
Dr. Lal PathLabs Ltd is a pathology lab based in India. It is involved in providing diagnostic services and other healthcare tests in the areas of pathology and radiology. The company operates laboratories for carrying out pathological diagnostic services in various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, and other pathological and radiological investigations. Its diagnostic services assist in preventing, monitoring, and treating diseases and improving health conditions. The company has business operations in India and other countries, of which maximum revenue is generated within India.
93GF Score

Get the complete analysis for NSE:LALPATHLAB

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,949.90
Price
₹1,735.83
GF Value